Cargando…

Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer

BACKGROUND: Increased health care costs have made it incumbent on health-care facilities and physicians to demonstrate both clinical and cost efficacy when recommending treatments. Though studies have examined the cost-effectiveness of adjuvant goserelin with radiotherapy for locally advanced prosta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Tsui Fen, Wang, Jung Der, Uen, Wu Ching
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296644/ https://www.ncbi.nlm.nih.gov/pubmed/22264299 http://dx.doi.org/10.1186/1471-2407-12-33

Ejemplares similares

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.
por: Dixon, A. R., et al.
Publicado: (1990)

Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
por: Jonat, W
Publicado: (2002)

Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
por: Jonat, W
Publicado: (2001)

Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
por: Hackshaw, Allan, et al.
Publicado: (2009)

Unsuspected Skin Metastasis of Adenocarcinoma of the Prostate in a Patient on Goserelin (Zoladex)
por: Mbaeri, Timothy Uzoma, et al.
Publicado: (2018)

A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
por: Lind, M. J., et al.
Publicado: (1992)

Goserelin Ovarian Ablation Failure in Premenopausal Women With Breast Cancer
por: Gupta, Aanchal, et al.
Publicado: (2021)

The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
por: Williams, M. R., et al.
Publicado: (1986)

Adjuvant hormonal therapy in premenopausal women with breast cancer
por: Smyth, Lillian, et al.
Publicado: (2015)

Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial
por: Li, Jian-wei, et al.
Publicado: (2018)

The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
por: Stein, R. C., et al.
Publicado: (1990)

Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover
por: Wilson, Caroline, et al.
Publicado: (2016)

Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer.
por: Bruning, P. F., et al.
Publicado: (1990)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer
por: Wang, Jiayu, et al.
Publicado: (2015)

Survey of clinicians on the use of adjuvant therapy for premenopausal women with breast cancer
por: Lee, Young-Won, et al.
Publicado: (2023)

Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer.
por: Bianco, A. R., et al.
Publicado: (1991)

Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1989)

Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy
por: Joly, F, et al.
Publicado: (2000)

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
por: Forward, D P, et al.
Publicado: (2004)

Prognostic Effects of Adjuvant Chemotherapy-Induced Amenorrhea and Subsequent Resumption of Menstruation for Premenopausal Breast Cancer Patients
por: Jeon, Se Jeong, et al.
Publicado: (2016)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

Controversies in hormonal adjuvant therapy for premenopausal patients
por: Howell, A
Publicado: (2009)

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer
por: De Placido, S, et al.
Publicado: (2005)

Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced Amenorrhea
por: Zhou, Juan, et al.
Publicado: (2015)

Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
por: Jonat, W.
Publicado: (1998)

Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2021)

Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology.
por: Buzzoni, R., et al.
Publicado: (1995)

The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer
por: Jensen, Maj-Britt, et al.
Publicado: (2018)

Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy
por: Yeo, Winnie, et al.
Publicado: (2017)

Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria
por: Jahn, B., et al.
Publicado: (2015)

Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer
por: Parisi, Francesca, et al.
Publicado: (2020)

Changes in ovarian function in premenopausal women with breast cancer undergoing adjuvant TC (docetaxel and cyclophosphamide) chemotherapy during a brief period of amenorrhea around the last chemotherapy cycle
por: Yoshimura, Keiko, et al.
Publicado: (2014)

The affect of goserelin on the QoL of women having chemotherapy for EBC: Results from the OPTION trial
por: R, Leonard, et al.
Publicado: (2020)

Delayed initiation of adjuvant chemotherapy in older women with breast cancer
por: Smith‐Graziani, Demetria, et al.
Publicado: (2020)

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice
por: Buono, Giuseppe, et al.
Publicado: (2022)

Adjuvant chemotherapy for early breast cancer.
por: Henderson, I. C.
Publicado: (1990)

Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial
por: NISHIMURA, REIKI, et al.
Publicado: (2013)

Adjuvant chemotherapy
por: Glimelius, B.
Publicado: (2013)

Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial
por: Yang, H, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_esl0llmjk8r04272np34thfo0u